Zobrazeno 1 - 10
of 163
pro vyhledávání: '"Yuen Tsang"'
Publikováno v:
Pulmonary Circulation, Vol 14, Iss 3, Pp n/a-n/a (2024)
Abstract Selexipag is an oral selective agonist of the prostacyclin receptor approved to treat adults with pulmonary arterial hypertension (PAH). Selexipag is initiated at a dose of 200 μg twice daily (bid) and usually titrated up by 200 μg bid wee
Externí odkaz:
https://doaj.org/article/ea14623c56694b43a0f9d5caea342257
Publikováno v:
The Clinical Respiratory Journal, Vol 17, Iss 12, Pp 1209-1222 (2023)
Abstract Background Oral selexipag, a prostacyclin pathway agent (PPA), is effective in patients with pulmonary arterial hypertension (PAH). The objective of this study is to assess the impact of initiating oral selexipag within 12 months of diagnosi
Externí odkaz:
https://doaj.org/article/6e90ef9b6af64431a304ddf7d0d0b8ba
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 3, Pp 741-756 (2023)
Abstract Introduction Patients with connective tissue disorders (CTD) and pulmonary arterial hypertension (PAH) have a poorer prognosis than those with other PAH etiologies. This study assessed the impact of CTD on healthcare outcomes among PAH patie
Externí odkaz:
https://doaj.org/article/b3ae782811fe4d53aefb60b787e2da4c
Autor:
Harrison W. Farber, Murali M. Chakinala, Michelle Cho, Robert P. Frantz, Andrew Frick, Lisa Lancaster, Scott Milligan, Ronald Oudiz, Sumeet Panjabi, Yuen Tsang, Steven D. Nathan
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 3, Pp n/a-n/a (2023)
Abstract Pulmonary arterial hypertension (PAH) is a rare, life‐limiting disease. PAH registries provide real‐world data that complement clinical trial data and inform treatment decisions. The TRIO comprehensive, integrated patient data repository
Externí odkaz:
https://doaj.org/article/9450ffb2f427410cb5f40faf8efb0c23
Autor:
Yuen Tsang, Sumeet Panjabi, Vienica Funtanilla, Hayley D. Germack, Marjolaine Gauthier‐Loiselle, Ameur M. Manceur, Stephanie Liu, Martin Cloutier, Patrick Lefebvre
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 2, Pp n/a-n/a (2023)
Abstract Pulmonary arterial hypertension (PAH) is commonly associated with connective tissue disorders (CTDs). This study provides a contemporary assessment of the economic burden of CTD + PAH and PAH in the United States. Eligible adult patients ide
Externí odkaz:
https://doaj.org/article/1a7802320de94b8fb059854cd36ebf1a
Publikováno v:
Pulmonary Therapy, Vol 6, Iss 1, Pp 79-92 (2019)
Abstract Introduction Release of the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines put increased emphasis on using combination therapy, either as upfront or sequential therapy among patients with pulmonary ar
Externí odkaz:
https://doaj.org/article/f362ffa7916b4121a0d338ca185a4354
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Two oral medications targeting the prostacyclin pathway are available to treat pulmonary arterial hypertension in the United States: oral treprostinil and selexipag. We compared real-world hospitalization in patients receiving these medications. A re
Externí odkaz:
https://doaj.org/article/7dd8fa23021c4d9db3ce6b84225325b5
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Patients with portal hypertension may develop pulmonary hypertension. The economic implications of these comorbidities have not been systematically assessed. We compared healthcare resource utilization and costs in the United States between patients
Externí odkaz:
https://doaj.org/article/e282b9d9dd44472bb193ed39d8517dda
Autor:
Robert P. Frantz, Jerrold W. Hill, Cassandra A. Lickert, Rolin L. Wade, Michele R. Cole, Yuen Tsang, William Drake
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited. This retrospective database analysis evaluated
Externí odkaz:
https://doaj.org/article/41c21a40aa214abca64be48f966f6d14
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 13 (2019)
Introduction: Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the prese
Externí odkaz:
https://doaj.org/article/a65a01f21c8e4a288a9ed33b4e7c2ba1